GlassScriptPhysician profile
Julie A Byrd
NPI 1245254465
$38,478.70
in general payments reported to CMS, 2019-2025
43 companies · $4,212 in 2025
The $4,212 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,685 · 2020: $1,846 · 2021: $4,571 · 2022: $5,065 · 2023: $7,090 · 2024: $11K · 2025: $4,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $7,800 · Travel and Lodging: $758 · Education: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,221.95 |
| Consulting Fee | $7,800.00 |
| Travel and Lodging | $757.66 |
| Education | $531.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,048.52 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $5,364.25 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $2,709.93 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Epi Health, LLC | $2,189.66 | 2019-2022 | |
| Galderma Laboratories, L.P. | $1,815.10 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Journey Medical Corporation | $1,545.14 | 2019-2025 | Emrosi |
| Novartis Pharmaceuticals Corporation | $1,392.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,112.18 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $994.91 | 2019-2025 | |
| Dermavant Sciences, INC. | $878.06 | 2022-2024 | Vtama |
| Leo Pharma INC. | $830.43 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $774.86 | 2019-2025 | Cabtreo, Arazlo, Siliq |
| E.R. Squibb & Sons, L.L.C. | $722.99 | 2022-2025 | Sotyktu |
| Ucb, INC. | $693.22 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $674.05 | 2019-2025 | Tavneos, Otezla, Otezla |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $628.71 | 2019-2025 | |
| Almirall LLC | $549.28 | 2019-2024 | Seysara, Klisyri |
| Lilly USA, LLC | $542.31 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $513.28 | 2023-2025 | Zoryve |
| Incyte Corporation | $506.28 | 2021-2025 | Opzelura |
| Avita Medical Americas, LLC | $500.00 | 2023 | Recell |
| Merz North America, INC. | $319.96 | 2019 | |
| Vyne Pharmaceuticals INC. | $318.66 | 2020-2021 | |
| Biofrontera INC. | $303.05 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $233.06 | 2023-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $216.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.61 | 2023-2025 | Spevigo, Cyltezo |
| Mayne Pharma Commercial LLC | $174.33 | 2019-2025 | |
| Organon LLC | $139.83 | 2024-2025 | Hadlima, Vtama |
| Allergan, INC. | $99.55 | 2019-2022 | |
| Revance Therapeutics, INC. | $95.24 | 2024 | Daxxify |
| Encore Dermatology INC. | $88.89 | 2019 | |
| Strata Skin Sciences, INC. | $71.36 | 2022-2025 | Xtrac |
| Sandoz INC. | $60.75 | 2020 | |
| Genentech USA, INC. | $47.52 | 2021 | |
| Prugen, INC. Pharmaceuticals | $33.50 | 2019 | |
| Sebela Pharmaceuticals INC. | $16.89 | 2020 | |
| Integra Lifesciences Corporation | $15.08 | 2021 | |
| Sensus Healthcare, INC. | $12.77 | 2019 | |
| Merck Sharp & Dohme LLC | $12.74 | 2019 | |
| Nabriva Therapeutics, Plc | $12.21 | 2021 | |
| Promius Pharma LLC | $11.46 | 2019 | |
| Dermira, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.